Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:53:05.494Z.
Calculation as of: 2026-10-06T14:53:05.494Z.
Quote observation: 2026-10-06T14:49:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
PEG RATIO
N/A
Monopar Therapeutics Inc.
Market Cap
$511.12M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $511.12M | N/A |
| 908 Devices Inc. (MASS)vs › | $511.81M | N/A |
| Altimmune, Inc. (ALT)vs › | $517.50M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $526.70M | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $501.86M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.79M | N/A |
| Oculis Holding AG (OCS)vs › | $494.52M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $534.74M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $544.38M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $554.35M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
